Curium Announces a Strategic Investment of Over €32 million in Saclay, France
Curium is investing over €32 million in Saclay, France, to establish a European production line for ¹⁷⁷Lu-PSMA-I&T, a therapy for metastatic castration-resistant prostate cancer, reinforcing France’s role in nuclear medicine. The move aligns with a €50 million investment program over five years and aims to meet growing European demand for targeted cancer treatments by 2035.
Curium is investing over €32 million in Saclay, France, to create a production line for ¹⁷⁷Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer. The facility will serve European demand for targeted prostate cancer therapies, positioning France as a leader in nuclear medicine innovation. This investment is part of Curium’s broader €50 million commitment in France over the past five years, reflecting confidence in the country’s industrial strength and scientific ecosystem. Saclay, Curium’s historic site, leverages France’s expertise in nuclear medicine, rooted in the legacy of the French Atomic Energy Commission (CEA). The facility will strengthen France’s care pathway and support the growing adoption of radioligand therapy (RLT), which combines molecular vectors with radioactive isotopes to target tumors directly. By 2035, France’s eligible patient pool for RLT could increase over tenfold, driven by advancements in cancer treatment. Curium employs over 750 people in France across 13 production sites, serving more than 200 nuclear medicine centers daily. The company’s global leadership in radiopharmaceuticals includes a portfolio of over 45 products for various cancers, with operations spanning 70 countries and a workforce of 5,000. This investment underscores France’s role in the European nuclear medicine value chain and aligns with Curium’s mission to expand access to innovative cancer therapies. The company’s CEO, Ciril Faia, highlighted France’s significance as a production hub, accounting for over 20% of Curium’s global revenue. Nuclear medicine, particularly RLT, is poised to become a cornerstone of modern cancer treatment, offering precise and targeted solutions. Isabelle Rouzou, SVP Quality and Operations, noted France’s scientific, industrial, and hospital ecosystem as key factors in the investment, creating opportunities for skilled workers and improving patient access to therapies.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.